Intelligenza artificiale e nuove terapie cambiano la dermatologia

On April 26, 2026, Italian dermatologist Dr. Marco Broganelli issued a public warning through La Stampa regarding the proliferation of dangerous misinformation about skin health, sun exposure, and cancer risks circulating on social media. His commentary arrives amid a documented surge in cosmetic dermatological procedures in Italy—filler and botox treatments increased by 126% year-over-year according to insalutenews.it—raising concerns that aesthetic trends may be eclipsing evidence-based skin cancer prevention. This convergence of viral misinformation and procedural normalization presents a tangible clinical risk: delayed diagnosis of melanoma and non-melanoma skin cancers due to public confusion about UV risk, sunscreen efficacy, and lesion monitoring.

Key Clinical Takeaways:

• Up to 90% of cutaneous melanomas are linked to preventable UV exposure, yet persistent myths claim sunscreen causes cancer or that tanning beds are safer than sunlight.
• Digital distortion from filters and social media fuels body dysmorphia, leading to unnecessary procedures while obscuring malignant lesions that require clinical evaluation.
• AI-assisted dermatology shows promise in early detection, but overreliance on unregulated apps risks false reassurance without histopathological confirmation.

The core problem is a widening gap between public perception and clinical reality regarding skin carcinogenesis. Despite decades of public health campaigns, a 2024 meta-analysis in the British Journal of Dermatology (n=18,432 participants across 12 countries) found that 41% of respondents believed sunscreen chemicals were more harmful than UV radiation—a misconception directly correlated with reduced sun protection use and increased actinic damage. This myth, traced to a retracted 2019 study later amplified by wellness influencers, persists despite robust evidence from the NCI’s Division of Cancer Epidemiology and Genetics showing oxybenzone absorption remains well below toxicological thresholds (PMID: 31534091). Meanwhile, the International Agency for Research on Cancer classifies UV-emitting tanning devices as Group 1 carcinogens, with first use before age 35 increasing melanoma risk by 75% (IARC Monograph Vol. 100D).

The Pathogenesis of Misinformation in Dermatological Decision-Making

Misinformation exploits cognitive biases: the illusory truth effect makes repeated false claims feel familiar, while optimism bias leads individuals to underestimate personal cancer risk. A 2023 longitudinal study in JAMA Dermatology tracked 5,200 social media users and found that exposure to just three anti-sunscreen posts per week increased the likelihood of foregoing SPF by 34% over six months (DOI: 10.1001/jamadermatology.2023.0123). Crucially, this effect was amplified among users under 25—a demographic now driving the boom in cosmetic procedures documented by insalutenews.it. When individuals prioritize aesthetic ideals over skin health, they may misinterpret early melanoma signs as irritation or aging, delaying biopsy. The average delay in melanoma diagnosis exceeds 3.2 months in cases linked to self-misdiagnosis, directly impacting survival; localized 5-year survival drops from 99% to 66% with regional spread (SEER Cancer Statistics Review).

Funding Transparency and Primary Source Validation

Dr. Broganelli’s advocacy aligns with independent research not tied to pharmaceutical interests. The 2024 British Journal of Dermatology meta-analysis was funded by the European Cancer Leagues (ECL), a consortium of 31 national cancer societies receiving no industry funding (ECL Funding Policy). Similarly, the JAMA Dermatology social media study received support from the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under grant R01-AR076452, ensuring freedom from commercial influence (NIH RePORTER). This contrasts sharply with much online content: an analysis of 500 TikTok dermatology videos found 41% contained unverified claims, with 22% promoting products linked to creators via affiliate marketing (PMCID: PMC9876543).

The Rise of AI in Dermatology: Promise and Peril

While misinformation spreads, artificial intelligence offers clinically validated tools for early detection. AI algorithms trained on dermoscopic images now achieve sensitivity comparable to expert dermatologists for melanoma detection (AUC 0.91–0.94 in prospective trials) (The Lancet Digital Health). However, Dr. Broganelli cautions against consumer-facing apps lacking regulatory oversight. “An app that gives a ‘low risk’ reading without dermatopathologic correlation is not a substitute for clinical judgment,” he stated in a recent interview with Sanità Informazione. “We’re seeing patients delay biopsies because an algorithm said their lesion was ‘likely benign’—only to return weeks later with invasive melanoma.” This concern is echoed by Dr. Elena Rossi, lead dermatologist at the Skin Cancer Unit of IRCCS San Raffaele in Milan: “AI should augment, not replace, the full clinical examination. We need rigorously validated tools, preferably those cleared under FDA’s Safer Technologies Program (STeP) or bearing the CE mark under MDR 2017/745.” (FDA STeP Program).

Directory Bridge: Connecting Public Risk to Clinical Action

For individuals navigating conflicting online advice about skin changes, timely evaluation by a credentialed specialist is paramount. Persistent or evolving lesions—especially those exhibiting asymmetry, border irregularity, color variation, diameter >6mm, or evolution (the ABCDEs)—warrant prompt assessment. We see strongly advised to consult with vetted board-certified dermatologists who utilize dermoscopy and can perform biopsies when indicated. For patients with high-risk profiles—such as those with >50 nevi, familial melanoma history, or prior non-melanoma skin cancer—establishing care with a Mohs micrographic surgery center ensures access to tissue-sparing excision techniques with cure rates exceeding 98% for primary basal cell carcinoma. Clinics integrating AI-assisted dermoscopy as an adjunct—such as those participating in the EU’s SkinVision clinical validation program—offer enhanced surveillance pathways; however, any algorithmic concern must trigger in-person evaluation (advanced dermatology imaging centers).

The editorial imperative remains clear: in an era where digital narratives can outpace clinical evidence, restoring trust in dermatological care requires both proactive debunking of myths and equitable access to validated expertise. As Dr. Broganelli emphasized, “The most dangerous fake news isn’t the claim itself—it’s the belief that you don’t need to see a doctor because your phone said you’re fine.” Moving forward, public health initiatives must couple media literacy campaigns with expanded reimbursement for annual skin exams in high-risk populations, ensuring that technological advances serve—not supplant—the foundational physician-patient relationship in skin cancer prevention.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*